EP-1302: SBRT in prostate cancer: is CyberKnife the only option?  by Dean, C. et al.
S488  2nd ESTRO Forum 2013 
Purpose/Objective: To investigate the advantages in dosimetry, 
patient comfort and positioning accuracy when using the newly 
developed Sagittilt® (Orfit Industries, Wijnegem, Belgium) prone 
breast board. 
Materials and Methods: A careful clinical introduction of Sagittilt® has 
been initiated: Phase 1: pre-clinical treatment planning study and 
Phase 2: prospective clinical trial (still ongoing). During the pre-
clinical phase, 14 patients with breast cancer were scanned in supine 
and prone position and treatment plans were created to investigate 
dosimetrical advantages of Sagittilt®. The second phase started with 
the clinical treatments of (to date) 5 patients in prone position. This 
early clinical phase focused on patient comfort assessed by an in-
house developed questionnaire completed by the patients. Positioning 
accuracy has been assessed by daily online cone-beam CT acquisition 
(pre-RT CBCT), followed by a post-RT CBCT in order to investigate 
stability of positioning over time. 
Results: The pre-clinical treatment planning study confirmed non-
significant differences on target coverage (V95%-107% of the PTV) and 
on heart dose, while a significant reduction of the ipsilateral lung and 
slightly higher dose to the contralateral breast were observed. The 
early clinical phase eliminated the increased contralateral breast 
dose, revealed good-excellent patient comfort, while the setup error 
remained low (individual systematic and random errors were: 0-3 mm 
and 0.8-2.5 mm). The residual error (ie. the error observed between 
the two CBCT) could rise up to 7 mm (at the 2nd patient Figure 1.) 
especially if treatment execution exceeds 10 minutes.  
 
Conclusions: Our methodology for the clinical introduction of 
Sagittilt® proved to be safe. Our current data showed promising 
results for dosimetry and positioning accuracy. Special attention 
should be paid to reduce the overall treatment time to keep residual 
error as low as possible. 
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Purpose/Objective: High-quality radiotherapy (RT) treatment 
planning requires the combination of information arising from multiple 
medical imaging modalities. For this reason, RT implies the setup and 
the management of complex flows of images between the various 
modalities and software of the hospital. Even though biomedical 
images are most commonly stored and transferred using the DICOM 
standard, it remains hard to automatize and optimize these clinical 
flows that are very specific to each hospital. This stems from the fact 
that programming the DICOM network protocol requires both a high 
level of familiarity with the DICOM standard as well as substantial 
experience in computer programming. This motivates the introduction 
of the Orthanc software in the medical practice to improve the RT 
imaging workflow. 
Materials and Methods: Orthanc is an open-source, easy-to-use, 
lightweight and scriptable DICOM store. It takes advantage of the 
DCMTK toolkit for powerful DICOM handling abilities. Multiple 
instances of Orthanc can be easily and freely deployed in the hospital 
network. Orthanc comes bundled with an embedded Web interface 
that allows the end-users to browse and interact with the content of 
the DICOM store from any computer. Orthanc can be setup as a bridge 
between multiple DICOM modalities, which improves the 
interoperability between proprietary systems by decoupling them. 
Furthermore, Orthanc features a rich scripting environment: It can be 
driven from any computer language to automate and optimize clinical 
processes. Orthanc is written in C++ for maximum speed, and 
emphasis is put on the quality and the automated validation of its 
source code. 
Results: Orthanc is currently used in our Institution to improve two 
real-world clinical processes. Firstly, Orthanc is deployed as a buffer 
for PET scans between Nuclear Medicine (NM) and RT departments. 
These images are indeed systematically purged from the Treatment 
Planning System (TPS) on a daily basis. Orthanc enables the RT 
physicists to immediately find the purged images and restore them 
back from Orthanc into the TPS on the fly, without any interaction 
with the NM team, hence accelerating the clinical processes. 
Secondly, another instance of Orthanc is configured to gather the in-
room images that are produced during the RT treatments. This opens 
the path to the automated assessment of the quality of the patient 
positioning and to the clinical research about adaptive radiotherapy in 
our hospital. 
Conclusions: The open-source Orthanc software provides medical 
physicists with a powerful environment to make the image flows more 
robust and automated in RT departments.  
 
EP-1302   
SBRT in prostate cancer: is CyberKnife the only option? 
C. Dean1, N. Macdougall1, R. Muirhead2 
1St Bartholomew's Hospital, Radiation Physics, London, United 
Kingdom  
2St Bartholomew's Hospital, Radiation Oncology, London, United 
Kingdom  
 
Purpose/Objective: Over recent years, there has been an increasing 
interest in the use of stereotactic body radiotherapy (SBRT) in the 
management of low and intermediate risk prostate adenocarcinoma. A 
number of small studies and single centre series have been published 
demonstrating biochemical progression free survival rates (bPFS) at 3 
to 4 years between 90% - 100%, with long term grade 3 rectal and 
urinary toxicity no higher than 3%. The majority of these series have 
used Cyberknife™ (Accuray Inc., Sunnyvale, CA) with an international 
randomised controlled study underway, comparing SBRT delivered 
using Cyberknife, to surgery and to conventionally fractionated 
intensity modulated radiotherapy. 
Materials and Methods: Six patients previously treated with 
conventional radical radiotherapy were selected to represent a typical 
range of prostate shapes and sizes. Delineation of the prostate alone 
(CTV) and all organs at risk (OARs) was performed by one consultant 
clinical oncologist. A margin of 3mm for CyberKnife and 5mm for 
Rapicarc were used to create PTVs. Plans that deliver at least 35Gy in 
5 fractions to at least 99% of the PTV (PTV35Gy>99%) were then 
created using Accuray Multiplan v.4.5 (Ray-tracing algorithm) and 
Varian Eclipse v.10 (AAA algorithm). SBRT dose constraints that are 
typically employed were used to optimise doses to the rectum and 
bladder without compromising PTV coverage (Rectum V18 <50%, V28 
<20% and V36 <1cc; bladder V18 <40%, V37 <10cc). Plans were 
transferred to a water equivalent phantom and delivered doses were 
measured for both systems using radiochromic film.  
Results: Both planning systems achieved a planned dose PTV 
heterogeneity of <13% in all six patients. The planned OAR constraints 
were achieved for all patients for both systems. We aim to dose 
escalate using both platforms to assess which platform is first to fail 
the constraints. Figure 1 shows an example of comparison CyberKnife 
and Rapidarc plans for the same patient.  
 
  
Conclusions: We have shown that in terms of both planned and 
delivered dosimetry, Rapidarc is comparable to Cyberknife in SBRT for 
prostate cancer. The additional benefit of arc therapy is the 
comparatively short delivery time. In addition there is both a larger 
availability of radiotherapy centres equipped to deliver arc therapy, 
and a larger number of arc capable machines within each centre. An 
international, platform independent, clinical trial is urgently required 
to confirm an equal clinical benefit with other platforms. 
 
